313 related articles for article (PubMed ID: 34265073)
1. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
3. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
4. Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3.
Chen L; Xu W; Yang Q; Zhang H; Wan L; Xin B; Zhang J; Guo C
Pharmacol Res; 2020 Aug; 158():104871. PubMed ID: 32413482
[TBL] [Abstract][Full Text] [Related]
5. Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model.
Chen L; Chen Y; Wang M; Lai L; Zheng L; Lu H
Eur J Pharmacol; 2024 Apr; 969():176429. PubMed ID: 38423241
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90.
Wu HY; Trevino JG; Fang BL; Riner AN; Vudatha V; Zhang GH; Li YP
Cells; 2022 Sep; 11(17):. PubMed ID: 36078164
[TBL] [Abstract][Full Text] [Related]
7. Ginsenoside Rd ameliorates muscle wasting by suppressing the signal transducer and activator of transcription 3 pathway.
Wijaya YT; Setiawan T; Sari IN; Park K; Lee CH; Cho KW; Lee YK; Lim JY; Yoon JK; Lee SH; Kwon HY
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3149-3162. PubMed ID: 36127129
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
9. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.
Seto DN; Kandarian SC; Jackman RW
J Biol Chem; 2015 Aug; 290(32):19976-86. PubMed ID: 26092726
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway.
Wang Y; Sun X; Yang Q; Guo C
Phytother Res; 2023 Aug; 37(8):3380-3393. PubMed ID: 37073890
[TBL] [Abstract][Full Text] [Related]
12. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
13. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
15. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
16. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
[TBL] [Abstract][Full Text] [Related]
17. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia.
Huot JR; Novinger LJ; Pin F; Bonetto A
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31915140
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.
Judge SM; Wu CL; Beharry AW; Roberts BM; Ferreira LF; Kandarian SC; Judge AR
BMC Cancer; 2014 Dec; 14():997. PubMed ID: 25539728
[TBL] [Abstract][Full Text] [Related]
19. Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles.
Fan M; Gu X; Zhang W; Shen Q; Zhang R; Fang Q; Wang Y; Guo X; Zhang X; Liu X
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2724-2739. PubMed ID: 36085573
[TBL] [Abstract][Full Text] [Related]
20. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
